For US Healthcare Professionals Only
A Sanofi Pasteur Company

Your shopping cart is empty
You are about to log out of

Would you like to place your order before you log out?

Log Out
Continue Shopping


Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed Combined with Inactivated Poliovirus Vaccine

Log in to order

About Quadracel Vaccine


Contraindications to vaccination with Quadracel vaccine include: severe allergic reaction (eg, anaphylaxis) to any ingredient of Quadracel vaccine or following any other diphtheria toxoid, tetanus toxoid, or pertussis-containing vaccine, or inactivated poliovirus vaccine; encephalopathy within 7 days after a previous dose of a pertussis-containing vaccine with no other identifiable cause; or a progressive neurologic disorder.

Carefully consider benefits and risks before administering Quadracel vaccine to persons with a history of: fever ≥105°F, hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting 3 hours within 48 hours after a previous pertussis-containing vaccine; seizures within 3 days after a previous pertussis-containing vaccine; Guillain-Barré syndrome occurring within 6 weeks following receipt of a prior vaccine containing tetanus toxoid; or adverse events after a previous dose of Quadracel vaccine or receipt of any other tetanus toxoid, diphtheria toxoid, or pertussis antigen-containing vaccine.

The most common local and systemic adverse reactions to Quadracel vaccine include pain, erythema, and edema at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur. Vaccination with Quadracel vaccine may not protect all individuals.


Quadracel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis.

A single dose of Quadracel vaccine is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine) and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed). .

Before administering Quadracel vaccine, please see accompanying full Prescribing Information.


CDC VIS Sheets

Vaccine Information Statement

Guides, Materials, & Brochures

Coding Quick Look

Vaccine Current Procedural Terminology (CPT®a) Code: 90696
National Drug Codes (NDC): N449281056210 ML0.5 (carton) or N449281056258 ML0.5 (vial)

Administration CPT Code:
Patients 18 years of age and under, with qualified counseling: 90460 x 1 and 90461 x 3


Patients of any age without qualified counseling: 90471 or 90472


Typical ICD-10 Code for the vaccine and it’s administration: Z23

aCPT is a registered trademark of the American Medical Association.


This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.